Preeclampsia ScreenSM | T1 is an advanced blood test that helps determine your patient’s risk for early onset preeclampsia. Performed between 10 weeks, 0 days and 13 weeks, 6 days gestation, the test combines personal history, ultrasound markers, blood pressure, and analysis of three biological markers in the patient’s blood to yield a risk assessment.
Uterine Artery Doppler Pulsatility Index
Need nuchal translucency or uterine artery doppler pulsatility index certification? We can help.
- Make sure the patient is sitting comfortably with her feet on the floor, legs uncrossed, for about 5 minutes.
- Blood pressure (BP) measured in both arms simultaneously.
- Recordings at 1-minute intervals until stable.
- Enter Left Arm and Right arm BP’s on NTD’s Test Requisition
- MAP is calculated by NTD Labs.
ASPRE trial: Aspirin from 12 weeks
The objectives of this study were to examine if the prophylactic use of low-dose aspirin from the first-trimester of pregnancy in women at increased risk for preterm PE can reduce the incidence of the disease.
“Women should be offered combined screening [i.e. algorithm combining maternal demographics with biochemical & biophysical markers] at 12 weeks, and the high risk group should be treated with aspirin, 150 mg per night, starting from 12 weeks through 36 weeks of pregnancy with a major expected reduction in the rate of preterm preeclampsia.”
Turn around time: results can be expected 2-5 business days from the time the sample is received at the laboratory.
Learn more about why NTD Eurofins has been the laboratory to trust for over 30 years.Learn More
Leave the billing worries to us! NTD works hard to ensure that the billing process is simple and easy for your patients.
Interested in sending samples?
We can help you get started!Contact Us for More Information